Sign in
Taking people in United StatesNo phase

Testing an Automated Insulin Delivery System in Adults With Type 2 Diabetes

Tests an automated insulin pump system in adults with type 2 diabetes.

Key facts

Who runs it
Insulet Corporation
Where
Asheville, Atlanta, Austin, Bloomington, Boston, Chattanooga, Chicago, Denver, Detroit, Idaho Falls, Los Angeles, McKinney, Minneapolis, New York, Newport Beach, Newport News, Portland, Rochester, Rosewell, San Antonio, Santa Barbara, Syracuse, Tampa, Vallejo, West Palm Beach, and Wilmington, United StatesSee the 27 sites
Trial code
Registry title
Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
Status
Recruiting
People taking part
350 people, planned
Started
30 Apr 2026
Expected to end
23 Sept 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Device: Omnipod M System with study CGM
  • Standard Therapy plus study CGM
Record updated
3 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who use insulin. It tests a fully closed loop insulin pump system called Omnipod M.

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
Type 2 diabetes for at least 6 months. Screening A1C 7.5% (58 mmol/mol) to under 14.0% (130 mmol/mol) for people on basal insulin only. A1C 6.0% (42 mmol/mol) to under 14.0% (130 mmol/mol) for all others.
Earlier treatment
On insulin for at least 3 months, with no change to the insulin plan for 6 weeks before the start. Basal-bolus insulin or basal insulin only. Cannot have used an automated insulin delivery pump in the past 3 months.

Main reasons for not taking part

  • Used an automated insulin delivery pump within the past 3 months
  • More than 1 severe low blood sugar episode in the past 6 months
  • More than 1 episode of diabetic ketoacidosis or hyperosmolar hyperglycemic state in the past 6 months, unrelated to an illness, a blocked or dislodged cannula, or first diagnosis
  • Pregnant or breastfeeding, or able to become pregnant and not using birth control
  • Systemic steroids within 4 weeks, or plans to take them during the 26-week trial phase

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Age at time of consent 18-75 years (inclusive)
  • Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months at time of screening
  • On insulin therapy for at least 3 months at time of screening, with no change to insulin regimen for 6 weeks prior (AID use within past 3 months excluded) to initiating baseline CGM data collection; Regimen is defined as (1) Basal-bolus insulin therapy (a) using multiple daily injections of insulin (MDI), (b) non-automated insulin pump, or (c) MDI with premix insulin; or (2) basal insulin only (without bolus insulin); Basal-bolus insulin therapy defined as use of a basal insulin (either long-acting or intermediate-acting (e.g., NPH) plus at least one mealtime insulin dose per day, or a non-automated insulin pump; Inhaled insulin may be used in addition to or instead of mealtime injections pre-study and as part of the Control group
  • For basal only users, screening A1C ≥7.5% and <14.0%. For basal bolus users (i.e., all others), screening A1C ≥6.0% and <14.0%; A1C measurement within 28 days prior to enrollment is acceptable
  • Willing to use only the following types of U-100 insulin while using the study pump: Humalog, Novolog, Admelog, Kirsty, Fiasp, Lyumjev or their generic/biosimilar equivalents
  • Willing to use only study-provided Libre 2 Plus or 3 Plus sensor during the study and not use another sensor
  • Deemed appropriate for pump therapy per Investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
  • No anticipated need to newly initiate noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose lowering effect during the 26-week RCT phase. (Additions or changes in these medications will be permitted during the Extension Phase)
  • If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose-lowering effect, prescribed dose has been stable for 6 weeks prior to baseline CGM collection; and there is not an anticipated need to increase the dose during the 26-week trial phase (dose reductions will be permitted for safety)
  • Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol
  • Willing to wear the system, including Pods, continuously throughout the 26-week trial phase
  • Willing and able to sign the Informed Consent Form (ICF)
  • Able to read and understand English
  • If of childbearing potential, willing and able to have pregnancy testing

Who cannot take part

  • Use of an automated insulin delivery pump within 3 months prior to screening
  • Current or known history of coronary artery disease that is not stable with medical management in the opinion of the investigator, including unstable angina, despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
  • Any planned surgery during the study which could be considered major in the opinion of the Investigator
  • Pregnant or lactating, or is of childbearing potential and not using an acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal)
  • Has taken systemic corticosteroids (oral or injectable) within 4 weeks or has had a local steroid injection (intraarticular, epidural) within 1 week prior to baseline CGM collection or plans to take oral or injectable steroids during the 26-week trial phase
  • Participation in another clinical study using an investigational drug or device within prior 30 days or intends to participate in any other interventional study during the 26-week trial phase
  • Any medical condition, which in the opinion of the Investigator, would put the participant at an unacceptable safety risk. This may include untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, unstable proliferative retinopathy, unstable psychiatric conditions such as eating disorders, drug or alcohol abuse
  • History of more than 1 episode of severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered consciousness, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions
  • History of more than 1 episode of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis
  • Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement
  • Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c
  • Plans to receive blood transfusion over the course of the 26-week trial phase
  • Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment
  • Participant is an employee of Insulet, an Investigator or a member of Investigator's study team, or immediate family member of any of the aforementioned

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Mountain Area Health Education CenterAsheville, United StatesContact: Michelle ChapmanTaking people
  • Atlanta Diabetes AssociatesAtlanta, United StatesContact: Amanda MaxsonTaking people
  • EmoryAtlanta, United StatesContact: Laya ChadalawadaTaking people
  • Texas Diabetes and EndocrinologyAustin, United StatesContact: Jennifer PerezTaking people
  • Indiana UniversityBloomington, United StatesContact: Kathy BohananTaking people
  • Joslin Diabetes CenterBoston, United StatesContact: Louise Ambler-OsbornTaking people
  • University of Diabetes and Endocrine ConsultantsChattanooga, United StatesContact: Kaitlyn HardenTaking people
  • Northwestern UniversityChicago, United StatesContact: Evelyn FronczykTaking people
  • University of Colorado DenverDenver, United StatesContact: Cari BergetTaking people
  • Henry Ford HealthDetroit, United StatesContact: Lydia OehringTaking people
  • Rocky Mountain DiabetesIdaho Falls, United StatesContact: Joann MaloneTaking people
  • University of Southern CaliforniaLos Angeles, United StatesContact: Martha WalkerTaking people
  • Tekton ResearchMcKinney, United StatesContact: Idolina GarciaTaking people
  • International Diabetes CenterMinneapolis, United StatesContact: Landon HaberTaking people
  • The Mount Sinai HospitalNew York, United StatesContact: Sophie BaumTaking people
  • HOAGNewport Beach, United StatesContact: Brittany DennisTaking people
  • Riverside Family Medicine Residency ProgramNewport News, United StatesContact: Elizabeth EckhartTaking people
  • Oregon Health and Science UniversityPortland, United StatesContact: Desiree OdgersTaking people
  • Mayo ClinicRochester, United StatesContact: Shafaq RizviTaking people
  • Endocrine Research Solutions, Inc.Rosewell, United StatesContact: Jessica TapiaTaking people
  • Tekton ResearchSan Antonio, United StatesContact: Sharon JonesTaking people
  • Sansum Diabetes Research InstituteSanta Barbara, United StatesContact: Maggie ShuimanTaking people
  • SUNY SyracuseSyracuse, United StatesContact: Suzan BzdickTaking people
  • University of South FloridaTampa, United StatesContact: Trang Ly, MBBS, PhDNo longer taking part
  • Touro University CaliforniaVallejo, United StatesContact: Tess CalinawanTaking people
  • Metabolic Research InstituteWest Palm Beach, United StatesContact: Amanda CalderonTaking people
  • AccellacareWilmington, United StatesContact: Cara InscoTaking people

About the trial

What the trial wants to find out

A multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults with type 2 diabetes using basal/bolus insulin therapy or basal-only insulin therapy, with the primary endpoint after 15 weeks and secondary analysis at 26 weeks; followed by an extension phase after completion of the 26-week trial where the Intervention group will continue to use Omnipod M and the Control group will crossover to use Omnipod M for 26 weeks

The 2 groups in the trial

  • Intervention group - Omnipod MTreatment being tested

    The Intervention group will be assigned the Omnipod M system with the study CGM

    Treatment: Device: Omnipod M System with study CGM

  • Control group - Pre-study insulin regimenExisting treatment, for comparison

    The control group will continue the use of pre-study insulin regimen with the study CGM.

    Treatment: Standard Therapy plus study CGM

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
EVOLVE: Evaluation of the Fully Closed Loop Omnipod® System for Safety and Efficacy in Adults With Type 2 Diabetes
Plain-language title
Testing an Automated Insulin Delivery System in Adults With Type 2 DiabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07521475, who can take part
Record updated
3 August 2026